AdaptImmune

Cell and Gene
Share

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4 (MAGE-A4), ADP-A2M10 (MAGE-A10), and ADP-A2AFP (AFP)) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The foundation of our TCR therapies is the work we did with NY-ESO SPEAR T-cells, which we transitioned to GSK in 2018, showing responses in two solid tumors and treating more than 90 patients in six different indications.

We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells.

Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.

Thank you for having us @sitcancer! It was great connecting with our colleagues in #cancer immunotherapy at #SITC2019. Next stop – #CTOS2019 pic.twitter.com/9gvNrohLOr

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.